CervoMed Inc. (CRVO) announced Tuesday that its RewinD-LB Phase 2b clinical trial evaluating neflamapimod in patients with dementia ...

Neflamapimod did not demonstrate statistically significant effects versus placebo on primary and secondary endpoints at 16 weeks——Favorable ...

A dad is hoping to make his family proud by taking on the World's Toughest Row to raise £100,000 for those living with Lewy ...

CervoMed Inc.’s stock cratered early Tuesday after the biotech company said a midstage trial of a treatment for patients with ...

CervoMed reports RewinD-LB trial results for neflamapimod in dementia with Lewy bodies, highlighting missed endpoints and ...

Knowledge of these five key types—Alzheimer’s disease, vascular dementia, Lewy body dementia, frontotemporal dementia, and ...

Cervomed Inc. executives said they intend to scrutinize low plasma drug concentrations that appeared to spoil results from the phase IIb Rewind-LB trial testing neflamapimod in patients with dementia ...

Objective To investigate the effect on survival of treatment with memantine in patients with dementia with Lewy bodies (DLB) and Parkinson's disease with dementia (PDD). Methods 75 patients with DLB ...

CervoMed said on Tuesday its experimental drug for a common degenerative brain disease did not meet the main or secondary ...

CervoMed (CRVO) announced topline data from the RewinD-LB Phase 2b clinical trial evaluating neflamapimod for the treatment of patients with dementia with Lewy bodies. DLB. The trial did not meet ...

Roth MKM lowered the firm’s price target on CervoMed (CRVO) to $4 from $45 and keeps a Buy rating on the shares. The company ...

No history of medication could be elicited. Dementia with Lewy bodies (DLB) is a clinically defined syndrome and is claimed to be the second most common type of degenerative dementia among older ...